PRINCETON, N.J., Nov. 8 /PRNewswire-FirstCall/ -- Medarex, Inc. announced today that at least five antibodies generated from Medarex's UltiMAb(R) technology in which Medarex wholly owns or has an economic interest through co-promote/profit sharing rights, royalties and/or equity ownership, are expected to be the subject of oral or poster presentations at the 71st Annual Meeting of the American College of Rheumatology (ACR), being held November 6-11, 2007 in Boston.
Golimumab (CNTO 148) and ustekinumab (CNTO 1275) Phase III or Phase II clinical data for inflammatory diseases in development by Medarex's licensing partner, Centocor, Inc.
On November 1, 2007, Johnson & Johnson announced that it will sponsor an analyst meeting and webcast on Thursday, November 8, 2007, from 5:00-6:00 P.M. Eastern Time to discuss late-stage compounds, including golimumab and ustekinumab.
Ofatumumab (HuMax-CD20) Phase II clinical data for rheumatoid arthritis in development by Medarex's licensing partner, Genmab A/S
MEDI-545 Phase I clinical data for systemic lupus erythematosus in development by Medarex's partner, MedImmune, Inc.
Abstracts and information about the ACR and its Annual Meeting may be found at www.rheumatology.org.
About Medarex
Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. More than 30 of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with seven of the most advanced product candidates currently in Phase III clinical trials. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its website at www.medarex.com.
Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.
CONTACT: Media, Jean Mantuano, Corporate Communications, Inc., x2221, or
Investor Relations, Laura S. Choi, x2216, both of Medarex, Inc.,
+1-609-430-2880
Web site: http://www.medarex.com/
Company News On-Call: http://www.prnewswire.com/comp/108265.html/
